An observational study in Kidney Stone, sponsored by Region Skane. Enrolling by invitation at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Region Skane · Observational
The goal of this clinical trial is to evaluate the proportion of ureteral stones ≤4 mm that pass spontaneously within 4 and 8 weeks and assess if pain, blood test (S-creatinine), stone size, stone location and hydronephrosis can predict stone passage. The participants will be asked to fill in a questionare regarding symptoms, give a blood test and undergo a follow-up computed tomography.
All patients with a diagnosis of ureteral stone ≤4 mm at the Emergency Department in Helsingborg will be asked to participate. If they give consent data regarding age, gender, stone size, stone location, hydronephrosis, S-creatinine, treatments and results from the follow up CT is extraced from the medical records.
598 studies on the registry are indexed under Kidney Calculi; 163 are open to participants now.
This study's planned enrollment of 1,600 is above the median of 144 across 110 observational studies indexed under Kidney Calculi.
Browse Kidney Calculi studies →Region Skane is the lead sponsor of 372 studies on the registry; 113 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients with acute renal colic where a CT within 24 hours shows a ureteral stone ≤ 4mm.
Exclusion Criteria:
Number of ureteral stones ≤ 4mm that pass spontaneously
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
Number of participants with residual pain
Residual pain is measured with VAS (visual analogue scale), values 0-10. VAS 0 = no pain and VAS 10 = worst possible pain.
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
QoL form including sick leave and return to full ADL
Questionnaire specifically designed for this study, including questions about pain (regarding pain: how often, how severe/ VAS, need for pain medication) and the ability/ inability to work as usual. VAS: visual analougus scale 0-10, 0 = no pain and 10 = worst possible pain.
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
Proportion of ureteral stone that have passed according to anatomical localisation, S-creatinine and presence of hydronephrosis.
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Region Skane